One stock that might be an intriguing choice for investors right now is CoLucid Pharmaceuticals, Inc. CLCD. This is because this security in the Medical – Biomedical and Genetics space is seeing solid ...

CoLucid Pharmaceuticals, Inc. CLCD was a big mover last session, as the company saw its shares rise over 7% on the day. The upside came after the company provided an interim update from a phase III ...

CLCD, a provider of children’s literature database products for educators and librarians in the United States, is releasing CLCD Enterprise Version 7.0, a milestone achievement that aims to transform ...

Towards the end of August, we published this piece detailing two major potential upside catalysts to keep an eye on early September. One of the companies we profiled was CoLucid Pharmaceuticals Inc ...

Yet CLCD’s high RSI value isn’t the only reason for investors to be concerned, as there has been some decidedly negative earnings estimate revisions in CoLucid Pharmaceuticals’ stock as of late. This ...

The successful funds run by legendary investors such as Dan Loeb and David Tepper make hundreds of millions of dollars for themselves and their investors by spending enormous resources doing research ...

Colucid Pharmaceuticals Inc (NASDAQ: CLCD) is acting great. It popped 1.60, or 4%, to 40.10, on 251,610 shares traded. It's right up against key resistance. The prior high was 40.50, and on Monday the ...

MoBoo by CLCD launches Version 4 with AI-powered recommendations, enhanced personalization, and a new focus on independent young readers ages 16-25. SOMERS POINT, NJ ...

On Wednesday, shares of biopharmaceutical company CoLucid Pharmaceuticals CLCD are skyrocketing, up around 32% in midday trading after Eli Lilly and Co. announced it is buying the company for a ...